S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:RVNC

Revance Therapeutics Stock Forecast, Price & News

$26.29
+0.58 (+2.26 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.92
Now: $26.29
$26.36
50-Day Range
$25.35
MA: $27.75
$29.97
52-Week Range
$11.78
Now: $26.29
$34.62
Volume514,034 shs
Average Volume453,380 shs
Market Capitalization$1.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Revance Therapeutics logo

Headlines

Recap: Revance Therapeutics Q4 Earnings
February 22, 2021 |  finance.yahoo.com
Revance Therapeutics's Earnings Outlook
February 19, 2021 |  finance.yahoo.com
Is RVNC A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
November 27, 2020 |  finance.yahoo.com
FDA defers BLA decision on Revance's frown lines treatment
November 25, 2020 |  seekingalpha.com
Endeavor lands biotech HQ for new Nashville high-rise
November 24, 2020 |  bizjournals.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400
Employees193
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$410,000.00
Book Value$5.00 per share

Profitability

Net Income$-159,430,000.00
Net Margins-5,818.87%

Miscellaneous

Market Cap$1.88 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

297th out of 1,972 stocks

Pharmaceutical Preparations Industry

138th out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$26.29
+0.58 (+2.26 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

Is Revance Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Revance Therapeutics?

Wall Street analysts have given Revance Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Revance Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Revance Therapeutics
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its earnings results on Sunday, February, 21st. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.01. Revance Therapeutics had a negative net margin of 5,818.87% and a negative trailing twelve-month return on equity of 85.72%.
View Revance Therapeutics' earnings history
.

How has Revance Therapeutics' stock price been impacted by COVID-19?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RVNC shares have increased by 46.3% and is now trading at $26.29.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RVNC?

7 brokers have issued 12 month price objectives for Revance Therapeutics' shares. Their forecasts range from $15.00 to $45.00. On average, they expect Revance Therapeutics' stock price to reach $32.83 in the next year. This suggests a possible upside of 24.9% from the stock's current price.
View analysts' price targets for Revance Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:
  • Mr. Mark J. Foley, Pres, CEO & Director (Age 56, Pay $866.13k)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 46, Pay $621.33k)
  • Dr. Abhay Joshi, COO, Pres of R&D and Product Operations (Age 58, Pay $699.21k)
  • Mr. Dustin S. Sjuts, Chief Commercial Officer of Aesthetics & Therapeutics (Age 41, Pay $658.02k)
  • Mr. Aubrey Rankin, Pres of Innovation & Technology and Director (Age 46)
  • Mr. Dwight Moxie, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway, VP of Marketing
  • Mr. Justin Ford, Sr. VP of HR & Head of People
  • Ms. Azita Nejad, Sr. VP of Technical Operations

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

Who are some of Revance Therapeutics' key competitors?

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.53%), JPMorgan Chase & Co. (6.50%), Alliancebernstein L.P. (4.61%), Jennison Associates LLC (3.31%), Rice Hall James & Associates LLC (1.68%) and Northern Trust Corp (1.15%). Company insiders that own Revance Therapeutics stock include Aubrey Rankin, Cyril Allouche and L Daniel Browne.
View institutional ownership trends for Revance Therapeutics
.

Which institutional investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Principal Financial Group Inc., Principal Financial Group Inc., Jennison Associates LLC, ExodusPoint Capital Management LP, SG Americas Securities LLC, HighTower Advisors LLC, and Essex Investment Management Co. LLC.
View insider buying and selling activity for Revance Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Revance Therapeutics stock?

RVNC stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., UBS Asset Management Americas Inc., JPMorgan Chase & Co., Wells Fargo & Company MN, Bamco Inc. NY, BlackRock Inc., Walleye Capital LLC, and Nuveen Asset Management LLC.
View insider buying and selling activity for Revance Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $26.29.

How much money does Revance Therapeutics make?

Revance Therapeutics has a market capitalization of $1.88 billion and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis.

How many employees does Revance Therapeutics have?

Revance Therapeutics employs 193 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

Where are Revance Therapeutics' headquarters?

Revance Therapeutics is headquartered at 7555 GATEWAY BLVD., NEWARK CA, 94560.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.